LegalZoom, the provider of online legal services, swung to a loss and missed analysts' expectations on adjusted earnings. The stock is lower.11 Nov 2021
Is LZ a buy?
Out of 9 analysts, 2 (22.22%) are recommending LZ as a Strong Buy, 4 (44.44%) are recommending LZ as a Buy, 3 (33.33%) are recommending LZ as a Hold, 0 (0%) are recommending LZ as a Sell, and 0 (0%) are recommending LZ as a Strong Sell.
Who Bought Zoom stock?
Stockholder Stake Shares bought / sold
------------------------------------ ----- --------------------
The Vanguard Group, Inc. 5.19% +87,502
Morgan Stanley Investment Managem 4.16% +611,248
Baillie Gifford & Co. 3.23% -128,943
BlackRock Fund Advisors 2.98% -90,165
Zoom stock closes down 14% after Wall Street slashes price targets. Shares of Zoom fell Tuesday after the video-chat company warned investors of a revenue slowdown. The report led Wall Street banks to slash price targets on the stock.23 Nov 2021
Why does a stock suddenly drop?
Stock prices change everyday by market forces. If more people want to buy a stock (demand) than sell it (supply), then the price moves up. Conversely, if more people wanted to sell a stock than buy it, there would be greater supply than demand, and the price would fall.
Is LegalZoom profitable?
LegalZoom has been operating profitably until the most recent quarter. The Company generated $408 million in 2020 with a $46 million operating profit. In 2020, the Company continued to increase revenues by 18% despite the pandemic to $470 million with $49 million in operating profits.3 Aug 2021
Will LegalZoom go public?
Among the flood of recent IPOs is LegalZoom.com (NASDAQ:LZ). This legal services platform went public on June 30 with the IPO pricing at $28.00 per share.22 Jul 2021
How long has LegalZoom been in business?
2001
Is Surgalign a good stock to buy?
Is Surgalign a buy right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Surgalign stock.
Is LegalZoom stock a buy?
Small businesses will always need quality legal help, and LegalZoom is positioning itself well to serve them. For investors who can stomach the volatility that is likely to accompany a recent IPO with a rich valuation (shares trade at nearly 16 times 2020 revenue as of this writing), this IPO stock is a buy.22 Jul 2021